Cargando…

Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center

Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Youhong, Zahid, Kashif Rafiq, Han, Yidi, Hu, Pengchao, Zhang, Dongdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947196/
https://www.ncbi.nlm.nih.gov/pubmed/35327685
http://dx.doi.org/10.3390/children9030307
_version_ 1784674381542195200
author Dong, Youhong
Zahid, Kashif Rafiq
Han, Yidi
Hu, Pengchao
Zhang, Dongdong
author_facet Dong, Youhong
Zahid, Kashif Rafiq
Han, Yidi
Hu, Pengchao
Zhang, Dongdong
author_sort Dong, Youhong
collection PubMed
description Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the explorative treatment of IMT. Methods: Patients with newly diagnosed IMT between January 2013 and December 2018 were included. Patients were grouped according to surgical margins and Intergroup Rhabdomyosarcoma Study Group (IRSG) staging. The clinical characteristic, therapeutic schedules, treatment response and clinical outcome were described. Results: Six patients were enrolled in this study, including two boys and four girls, with a median age of 57 months (range 10–148 months). Among them, five patients were anaplastic lymphoma kinase positive. Four patients achieved complete remission and two patients attained partial remission after treatment with this protocol. All patients were alive after a median follow-up of 4 years (range 3–7 years). The most common treatment-related adverse reaction was myelosuppression. Conclusion: In this study, we demonstrated that IMT has a good prognosis and the treatment selected according to risk stratification was effective and feasible.
format Online
Article
Text
id pubmed-8947196
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89471962022-03-25 Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center Dong, Youhong Zahid, Kashif Rafiq Han, Yidi Hu, Pengchao Zhang, Dongdong Children (Basel) Brief Report Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the explorative treatment of IMT. Methods: Patients with newly diagnosed IMT between January 2013 and December 2018 were included. Patients were grouped according to surgical margins and Intergroup Rhabdomyosarcoma Study Group (IRSG) staging. The clinical characteristic, therapeutic schedules, treatment response and clinical outcome were described. Results: Six patients were enrolled in this study, including two boys and four girls, with a median age of 57 months (range 10–148 months). Among them, five patients were anaplastic lymphoma kinase positive. Four patients achieved complete remission and two patients attained partial remission after treatment with this protocol. All patients were alive after a median follow-up of 4 years (range 3–7 years). The most common treatment-related adverse reaction was myelosuppression. Conclusion: In this study, we demonstrated that IMT has a good prognosis and the treatment selected according to risk stratification was effective and feasible. MDPI 2022-02-24 /pmc/articles/PMC8947196/ /pubmed/35327685 http://dx.doi.org/10.3390/children9030307 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Dong, Youhong
Zahid, Kashif Rafiq
Han, Yidi
Hu, Pengchao
Zhang, Dongdong
Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
title Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
title_full Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
title_fullStr Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
title_full_unstemmed Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
title_short Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
title_sort treatment of pediatric inflammatory myofibroblastic tumor: the experience from china children’s medical center
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947196/
https://www.ncbi.nlm.nih.gov/pubmed/35327685
http://dx.doi.org/10.3390/children9030307
work_keys_str_mv AT dongyouhong treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter
AT zahidkashifrafiq treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter
AT hanyidi treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter
AT hupengchao treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter
AT zhangdongdong treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter